Mylan nabs exclusive Sovaldi, Harvoni deal in India; Bidvest bids $515M for full control of Adcock; Novo sees up to $335M from NNIT spinoff;

Medicine

@FiercePharma: Brain cancer therapy pioneered in dogs wins NCI grant for human development. More | Follow @FiercePharma

@CarlyHFierce: Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash. Release | Follow @CarlyHFierce

> U.S.-based Mylan ($MYL) signed up with Gilead Sciences ($GILD) as its exclusive distributor for branded hepatitis C drugs Sovaldi and Harvoni in India; Mylan was already one of the drugmakers licensed to sell generic versions of the meds. Release

> South African conglomerate Bidvest has offered about $515 million to gain full control of drugmaker Adcock Ingram; it currently owns a 34.5% stake in the generics maker. Report

> Novo Nordisk ($NVO) says it expects to rake in up to 2.2 billion kroner ($335 million) in a public stock offering for 40% of its technology subsidiary, NNIT, at 100 to 120 kroner per share. Report

> Pfizer ($PFE) says the FDA accepted its application for a new use for Rapamune (sirolimus), its transplant drug, to treat a rare, often fatal lung disease, lymphangioleiomyomatosis. Release

> Japanese regulators slapped Gilead Sciences for failing to report side effects of three drugs awaiting approval in that country, but already on the market elsewhere. Report

Medical Device News

@FierceMedDev: J&J readies to rid itself of Cordis--for as much as $2B to Cardinal Health. More | Follow @FierceMedDev

@VarunSaxena2: Reg. standards may be for NGS materials, methods & performance. Specific for each area (oncology, germline mutations etc) #PrecisionMedicine. | Follow @VarunSaxena2

@EmilyWFierce: Bayer feels sting of mixed decision from NICE for Eylea's use in diabetics. Article | Follow @EmilyWFierce

> First adhesive varicose vein treatment wins FDA approval. More

> Advisory panel recommends FDA approval of VertiFlex's spinal implant. Story

Biotech News

@FierceBiotech: Merck KGaA carves into MS R&D after a string of setbacks. Story | Follow @FierceBiotech

@JohnCFierce: $LLY, that wunderkind of drug R&D, delays peglispro after all and Tim Anderson sounds taps. Release | Follow @JohnCFierce

@DamianFierce: Big day for Tularik expats, particularly the ones at Flexus and NGM. Story | Report | Follow @DamianFierce

> Celldex jumps after gaining an FDA 'breakthrough.' More

> Bristol-Myers bags IDO immunotherapy in $1.25B buyout of fledgling Flexus. Article

Biotech IT News

> AstraZeneca picks Labguru to improve collaborations with academia. More

> FDA puts cloud storage and Google-esque search tools on precision medicine road map. Story

> Big Data digging yields unprecedented road map of the epigenome. Article

> BGI investor: It is the database they are building that will make them formidable. Report

> Transcriptic snags $8.5M to add capabilities at robot-run lab. News

CRO News

> LabCorp seals its $6B deal for Covance. Article

> After a $300M IPO, PRA forecasts a big 2015. More

> Theorem partners up for patient testing. Report

> Parexel stretches out its site network to speed up enrollment. Story

> WuXi borrows $165M to bankroll more M&A. Item

Animal Health News

> Jaguar posts positive trial results on lead prescription drug for dogs. Item

> Patterson misses on sales and earnings but reaffirms fiscal 2015 guidance. Report

> Australia's Integrated Animal Health to open offices in U.S. Story

> Brain cancer therapy pioneered in dogs wins NCI grant for human development. News

> Dogs get pulled into the medical marijuana debate. Article

And Finally... The U.S. military's health plans spent $84 million on erectile dysfunction meds last year for its beneficiaries, including active-duty personnel, retirees and eligible family members. Report

Read more on